Sugi Predict

Sugi Predict / Compounds / SCHEMBL2402087

SCHEMBL2402087

SCHEMBL2402087

CC(O)Cc1nc(N)c2[nH]cnc2n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDPK1 O15530 1/20 0.51
▸ GDA Q9Y2T3 1/20 0.51
▸ CDK1 P06493 7/20 0.43
▸ CCNB1 P14635 7/20 0.43
▸ CCNA2 P20248 7/20 0.43
▸ CDK2 P24941 7/20 0.43
▸ CCNA1 P78396 7/20 0.43
▸ PI4KA P42356 2/20 0.41
▸ PI4K2B Q8TCG2 2/20 0.41
▸ PI4K2A Q9BTU6 2/20 0.41
▸ PI4KB Q9UBF8 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ DRD3 P35462 1/20 0.41
▸ XDH P47989 1/20 0.41
▸ LRRK2 Q5S007 1/20 0.41
▸ KDR P35968 1/20 0.39
▸ AURKB Q96GD4 1/20 0.39
▸ POLA1 P09884 1/20 0.39
▸ MGMT P16455 2/20 0.39
▸ MAP3K5 Q99683 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29384383 0.86 PDPK1 (0.53) PDPK1GDACDK1CCNB1CCNA2
SCHEMBL25860 0.86 PDPK1 (0.53) PDPK1GDACDK1CCNB1CCNA2
SCHEMBL1982409 0.85 PDPK1 (0.51) PDPK1GDACDK1CCNB1CCNA2
SCHEMBL2909569 0.84 PDPK1 (0.50) PDPK1GDACDK1CCNB1CCNA2
SCHEMBL16620498 0.84 PDPK1 (0.50) PDPK1GDACDK1CCNB1CCNA2
SCHEMBL28144662 0.83 PDPK1 (0.46) PDPK1GDACDK1CCNB1CCNA2
SCHEMBL1924592 0.79 PDPK1 (0.59) PDPK1GDACDK1CCNB1CCNA2
SCHEMBL9176120 0.79 PDPK1 (0.59) PDPK1GDACDK1CCNB1CCNA2
SCHEMBL29592683 0.79 PDPK1 (0.59) PDPK1GDACDK1CCNB1CCNA2
SCHEMBL30150749 0.79 PDPK1 (0.51) PDPK1GDACDK1CCNB1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111961081-B Preparation method of (R) -2- (2-methoxypropyl phosphate) -adenine 北京鑫开元医药科技有限公司 2021-03-09 — — CN claimed
CN-111961081-A Preparation method of (R) -2- (2-methoxypropyl phosphate) -adenine 北京鑫开元医药科技有限公司 2020-11-20 — — CN claimed
US-20180111938-A1 Synthesis of Intermediates Used in the Manufacture of Anti-HIV Agents CBZ INVEST LTD (GB) 2018-04-26 — — US claimed
CN-107573381-A A kind of synthetic method of tenofovir 广东肇庆星湖生物科技股份有限公司 2018-01-12 — — CN claimed
CN-104817593-B Half fumaric acid tenofovir Chinese mugwort draws the synthesis technique of phenol amine key intermediate 广州同隽医药科技有限公司 2016-11-16 — — CN claimed
WO-2016178162-A1 SYNTHESIS OF INTERMEDIATES USED IN THE MANUFACTURE OF ANTI-HIV AGENTS CBZ INVESTMENTS LTD. (GB) 2016-11-10 — — WO claimed
CN-101574356-A Tenofovir disoproxil pharmaceutical salt and preparations thereof HEILONGJIANG CALIFORNIA INTERN (CN) 2009-11-11 — — CN claimed
CN-111961081-B Preparation method of (R) -2- (2-methoxypropyl phosphate) -adenine 北京鑫开元医药科技有限公司 2021-03-09 — — CN disclosed
CN-111961081-A Preparation method of (R) -2- (2-methoxypropyl phosphate) -adenine 北京鑫开元医药科技有限公司 2020-11-20 — — CN disclosed
CN-106632340-B A method of synthesis tenofovir intermediate 深圳市万物生医药研发有限公司 2018-09-04 — — CN disclosed
CN-106588932-B A kind of preparation method of tenofovir intermediate 郑州泰丰制药有限公司 2018-08-17 — — CN disclosed
CN-106588932-B A kind of preparation method of tenofovir intermediate 郑州泰丰制药有限公司 2018-08-17 — — CN disclosed
CN-108358968-A A kind of preparation method of high-purity tenofovir 山东科兴生物制品有限公司 2018-08-03 — — CN disclosed
CN-103848869-B The method preparing tenofovir 上海医药工业研究院 2016-12-21 — — CN disclosed
US-8759515-B2 Process for the preparation of tenofovir disoproxil fumarate MYLAN LABORATORIES LIMITED (IN) 2014-06-24 — — US disclosed
EP-2545063-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF TENOFOVIR DISOPROXIL FUMARATE Matrix Laboratories Ltd (IN) 2013-01-16 — — EP disclosed
US-20130005969-A1 PROCESS FOR THE PREPARATION OF TENOFOVIR DISOPROXIL FUMARATE MYLAN LABORATORIES LIMITED (IN) 2013-01-03 — — US disclosed
WO-2011111074-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF TENOFOVIR DISOPROXIL FUMARATE MATRIX LABORATORIES LTD (IN) 2011-09-15 — — WO disclosed
EP-0998480-A1 NUCLEOTIDE ANALOG COMPOSITION AND SYNTHESIS METHOD GILEAD SCIENCES, INC. (US) 2000-05-10 — — EP disclosed
WO-1999005150-A1 NUCLEOTIDE ANALOG COMPOSITION AND SYNTHESIS METHOD GILEAD SCIENCES, INC. (US) 1999-02-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180111938-A1 Synthesis of Intermediates Used in the Manufacture of Anti-HIV Agents CBR3, CBR1, DCXR PDPK1 3290/4885GDA 1995/4885CDK1 1320/4885
US-20130005969-A1 PROCESS FOR THE PREPARATION OF TENOFOVIR DISOPROXIL FUMARATE TYMP, PNP, MTAP PDPK1 236/4885GDA 372/4885CDK1 1809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.